Welcome!

News Feed Item

Global Pharmaceutical Survey 2013-2014 - Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry

NEW YORK, Feb. 20, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Pharmaceutical Survey 2013-2014 - Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry

http://www.reportlinker.com/p0795162/Global-Pharmaceutical-Survey-2013-2014---Market-Trends-Buyer-Spend-and-Procurement-Strategies-in-the-Global-Pharmaceutical-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Product Synopsis
"Global Pharmaceutical Survey 2013-2014: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry" is a new report by ICD Research that analyzes how pharmaceutical industry companies' procurement expenditures, business strategies, and practices are set to change in 2013-2014. Additionally, this report also presents comparative analysis between four years of survey results (wherever applicable). This report gives access to category-level spending outlooks, budgets, supplier selection criteria, business challenges, and investment opportunities of leading purchase decision makers. The report also identifies the future growth of buyers and suppliers, MandA, capital expenditure, staff hiring, and e-procurement. This report not only grants access to the opinions and strategies of business decision makers and competitors, but also examines their actions surrounding business priorities, as well as access to information categorized by region, company type, and size.

Introduction and Landscape
Why was the report written?
This report is the result of an extensive survey drawn from ICD Research's exclusive panel of leading global pharmaceutical industry executives; it provides data and analysis on buyer expenditure, procurement, and developments within the global pharmaceutical industry. The report includes key topics such as global pharmaceutical industry buyer expenditure and procurement behaviours and strategies, and identifies the threats and opportunities within the global pharmaceutical industry, economic outlook trends, and business confidence within global pharmaceutical executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives' attitude and changing behaviours, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, ICD Research created this primary-research based report by gathering the opinions of multiple stakeholders in the value-chain of the global pharmaceutical industry.

What is the current market landscape and what is changing?
Executives from the global pharmaceutical industry anticipate an increase in levels of consolidation, with 61% of respondents projecting an increase in MandA activities in 2013.

What are the key drivers behind recent market changes?
The need for new product pipelines, new product acquisition, patent expiries, cost containment and credit availability have prompted companies to consolidate positions and look for merger and MandA acquisition.

What makes this report unique and essential to read?
This report is the result of an extensive survey drawn from ICD Research's exclusive panel of leading global pharmaceutical industry executives; it provides data and analysis on buyer expenditure, procurement, and developments within the global pharmaceutical industry. The report includes key topics such as global pharmaceutical industry buyer expenditure and procurement behaviours and strategies, and identifies the threats and opportunities within the global pharmaceutical industry, economic outlook trends, and business confidence within global pharmaceutical industry executives. Additionally, this report also presents comparative analysis between four years of survey results (wherever applicable).

Key Features and Benefits
Project industry trends and revenue growth expectations in 2013, and understand business confidence to make informed business decisions.

Drive revenues by understanding future product investment areas and key growth regions.

Uncover key challenges and opportunities, and identify the key actions required to maintain and win buyer business.

Formulate effective sales and marketing strategies by identifying how buyer budgets are changing and the direction of spending in the future. Better promote your business by aligning your capabilities and business practices with your customer's changing needs

Secure stronger customer relationships by understanding the behaviour and changing strategies of industry buyers.

Key Market Issues
China, Brazil and India are the important emerging markets to offer growth in 2013.

'Market uncertainty', 'responding to price pressure', 'rising competition' and 'regulatory changes' are the leading business concerns for the global pharmaceutical industry in 2013.

Overall, for 2013, the average size of the annual procurement budget for global pharmaceutical industry buyer respondents is projected at US$127 million, against US$127 million in 2012 and US$110 million in 2011.

'Price', 'level of service' and 'existing relationship with supplier' are considered the most important factors for supplier selection in the global pharmaceutical industry, while 'environmental records and CSR', 'brand reputation' and 'proximity of supplier operations' are considered the least important.

While 16% of buyer respondents from the global pharmaceutical industry are willing to implement e-procurement in 2013 or beyond, 32% are already in the different stages of implementation ('partially implemented', 'completely implemented', and 'evaluation or pilot use')

Key Highlights
An analysis of revenue growth expectations by senior level respondents reveals that 62% are 'more optimistic' about their company's revenue growth in 2013.

A significant percentage of pharmaceutical manufacturing industry respondents highlighted that capital expenditure towards 'new product development', 'employee training', and 'IT infrastructure development' would increase in 2013.

The top three priorities for global pharmaceutical industry buyer respondents in 2013 are 'new products and services', 'improve operational efficiency' and 'expand in current markets'.

A total of 49% of respondents from pharmaceutical manufacturing companies, 68% of respondents from CROs and CMOs companies, and 64% of respondents from pharmaceutical industry supplier companies anticipate an increase of their current workforce in 2013.

Survey results show that respondents from the global pharmaceutical industry identified the US to offer the highest growth potential among developed countries in 2013-2014.

Table of Contents

1 Introduction
1.1 What is This Report About?
1.2 Definitions
1.3 Methodology
1.4 Profile of Survey Respondents: Global Pharmaceutical Industry
1.4.1 Global pharmaceutical industry: profile of buyer respondents
1.4.2 Global pharmaceutical industry: profile of supplier respondents
2 Executive Summary
3 Global Pharmaceutical Industry Dynamics
3.1 Revenue Growth Projections in the Global Pharmaceutical Industry
3.1.1 Revenue growth projections by company type
3.1.2 Revenue growth projections by region
3.1.3 Revenue growth projections by company turnover
3.1.4 Global pharmaceutical industry: revenue growth expectations by senior level respondents
3.2 Future Developments in Business Structure in the Global Pharmaceutical Industry
3.2.1 Future developments in business structure by buyers
3.2.2 Future developments in business structure by suppliers
3.2.3 Future developments in business structure by region
3.2.4 Future developments in business structure by company turnover
3.2.5 Future developments in business structure by senior level respondents
3.3 Change in Leading Company Strategies in the Global Pharmaceutical Industry
3.3.1 Change in leading company strategies by buyers
3.3.2 Change in leading company strategies by suppliers
3.3.3 Change in leading company strategies by region
3.3.4 Change in leading company strategies by company turnover
3.4 Merger and Acquisition (MandA) Activity Projections in the Global Pharmaceutical Industry
3.4.1 MandA activity projections by buyers
3.4.2 MandA activity projections by suppliers
3.4.3 MandA activity projections by region
3.4.4 MandA activity projections by company turnover
3.4.5 MandA activity projections by purchasing decision authority
3.4.6 Global pharmaceutical industry - expand abroad Vs MandA activity projections
3.5 Estimation of Capital Expenditure in the Global Pharmaceutical Industry
3.5.1 Estimation of capital expenditure by buyers
3.5.2 Estimation of capital expenditure by suppliers
3.5.3 Estimation of capital expenditure by region
3.5.4 Estimation of capital expenditure by company turnover
3.6 Planned Change in Staff Recruitment Activity in the Global Pharmaceutical Industry
3.6.1 Planned change in staff recruitment activity by buyers
3.6.2 Planned change in staff recruitment activity by suppliers
3.6.3 Planned change in staff recruitment activity by region
3.6.4 Planned change in staff recruitment activity by company turnover
4 Global Pharmaceutical Industry Market Growth Outlook
4.1 Global Pharmaceutical Industry: Demand in Emerging Markets
4.1.1 Demand in emerging markets by buyers
4.1.2 Demand in emerging markets by suppliers
4.1.3 Demand in emerging markets by region
4.1.4 Demand in emerging markets by company turnover
4.2 Global Pharmaceutical Industry - Growth Projections in Developed Countries
4.2.1 Growth projections in developed countries by buyers
4.2.2 Growth projections in developed countries by suppliers
4.2.3 Growth projections in developed countries by region
4.2.4 Growth projections in developed countries by company turnover
5 Threats and Opportunities for the Global Pharmaceutical Industry
5.1 Global Pharmaceutical Industry: Leading Business Concerns for 2013-2014
5.1.1 Leading business concerns for 2013-2014 by company type
5.1.2 Leading business concerns for 2013-2014 by region
5.1.3 Leading business concerns for 2013-2014 by company turnover
5.2 Global Pharmaceutical Industry: Key Supplier Actions to Maintain and Win Buyer Business
5.2.1 Actions to maintain and secure buyer business by buyers
5.2.2 Actions to maintain and secure buyer business by region
5.2.3 Actions to maintain and secure buyer business by company turnover
5.2.4 Actions to maintain and secure buyer business by purchasing decision authority
6 Global Pharmaceutical Industry Buyer Expenditure Activity
6.1 Annual Procurement Budgets in the Global Pharmaceutical Industry
6.1.1 Revenue growth vs. procurement budget
6.1.2 Annual procurement budgets by company type
6.1.3 Annual procurement budgets by region
6.1.4 Annual procurement budgets by company turnover
6.1.5 Annual procurement budgets by senior level respondents
6.2 Planned Change in Procurement Expenditure in the Global Pharmaceutical Industry
6.2.1 Planned change in procurement expenditure by buyer type
6.2.2 Planned change in procurement expenditure by region
6.2.3 Planned change in procurement expenditure by company turnover
6.2.4 Planned change in procurement expenditure vs. revenue growth optimism
6.2.5 Planned change in procurement expenditure vs. cost containment
6.3 Planned change in Procurement Expenditure by Product and Service Category
6.3.1 Planned change in procurement expenditure by product and service category - region
6.3.2 Planned change in procurement expenditure by product and service category - company turnover
6.4 Global Pharmaceutical Industry: Variations in Regional Supplier Prices
6.4.1 Variations in regional supplier prices by company type
6.4.2 Variations in regional supplier prices by region
6.4.3 Variations in regional supplier prices by company turnover
7 Global Pharmaceutical Industry: Procurement Behaviors and Strategies
7.1 Global Pharmaceutical Industry: Critical Success Factors for Supplier Selection
7.2 E-procurement in the Global Pharmaceutical Industry
7.2.1 E-procurement in the global pharmaceutical industry by buyer type
7.2.2 E-procurement in the global pharmaceutical industry by region
7.2.3 E-procurement in the global pharmaceutical industry by company turnover
8 Appendix
8.1 Global Pharmaceutical Industry Survey Results- Closed Questions
8.2 Methodology
8.3 Contact us
8.4 About ICD Research
8.5 Disclaimer

List of Tables

Table 1: Global Pharmaceutical Industry Survey Respondents by Company Type, 2013
Table 2: Global Pharmaceutical Industry Buyer Respondents by Job Role (%), 2013
Table 3: Global Pharmaceutical Industry Buyer Respondents by Region (%), 2013
Table 4: Global Pharmaceutical Industry Buyer Respondents by Company Turnover (%), 2013
Table 5: Global Pharmaceutical Industry Supplier Respondents by Job Role (%), 2013
Table 6: Global Pharmaceutical Industry Supplier Respondents by Region (%), 2013
Table 7: Global Pharmaceutical Industry Supplier Respondents by Company Turnover (%), 2013
Table 8: Revenue Growth Optimism in the Global Pharmaceutical Industry (%), 2010-2013
Table 9: Revenue Growth Optimism in the Global Pharmaceutical Industry by Buyers (%), 2010-2013
Table 10: Revenue Growth Optimism in the Global Pharmaceutical Industry by Suppliers (%), 2010-2013
Table 11: Revenue Growth Optimism in the Global Pharmaceutical Industry by Region (%),2013
Table 12: Revenue Growth Optimism in the Global Pharmaceutical Industry by Turnover (%), 2013
Table 13: Revenue Growth Optimism by Senior Level Respondents - Global Pharmaceutical Industry (%), 2013
Table 14: Key Expected Changes in Business Structure by Buyers - Global Pharmaceutical Industry (%), 2013
Table 15: Key Expected Changes in Business Structure by Suppliers - Global Pharmaceutical Industry (%), 2013
Table 16: Key Expected Changes in Business Structure by Turnover - Global Pharmaceutical Industry (%), 2013
Table 17: Key Expected Changes In Business Structure by Senior Level Respondents - Global Pharmaceutical Industry (%), 2013
Table 18: Change in Leading Company Strategies by Buyers - Global Pharmaceutical Industry (%), 2013
Table 19: Change in Leading Company Strategies by Suppliers - Global Pharmaceutical Industry (%), 2013
Table 20: Change in Leading Company Strategies by Region - Global Pharmaceutical Industry (%), 2013
Table 21: MandA Activity Projections - Global Pharmaceutical Manufacturers' Industry (%), 2010-2013
Table 22: MandA Activity Projections - Global CROs and CMOs (%), 2010-2013
Table 23: MandA Activity Projections - Global Pharmaceutical Industry Suppliers (%), 2010-2013
Table 24: Global Pharmaceutical Industry MandA Activity Projections by Region (%), 2013
Table 25: Global Pharmaceutical Industry MandA Activity Projections by Turnover (%), 2013
Table 26: Global Pharmaceutical Industry MandA Activity Projections by Purchasing Decision Authority (%), 2013
Table 27: Global Pharmaceutical Industry - Expand Abroad vs. MandA Activity Projections(%), 2013
Table 28: Change in Capital Expenditure by Global Pharmaceutical Industry Manufacturers(%), 2013
Table 29: Change in Capital Expenditure by Global CROs and CMOs (%), 2013
Table 30: Change in Capital Expenditure by Pharmaceutical Industry Suppliers (%), 2013
Table 31: Global Pharmaceutical Industry - Increase in Capital Expenditure by Region (%), 2013
Table 32: Global Pharmaceutical Industry Manufacturers - Planned Change in Staff Recruitment (%), 2013
Table 33: Global Pharmaceutical Industry Suppliers - Planned Change in Staff Recruitment Activity (%), 2013
Table 34: Global Pharmaceutical Industry - Planned Change in Staff Recruitment Activity by Region (%), 2013
Table 35: Global Pharmaceutical Industry - Planned Change in Staff Recruitment Activity by Turnover (%), 2013
Table 36: Global Pharmaceutical Industry Manufacturers - Demand in Emerging Markets (%), 2013
Table 37: Global Pharmaceutical Industry CROs and CMOs - Demand in Emerging Markets (%), 2013
Table 38: Global Pharmaceutical Industry Suppliers - Demand in Emerging Markets (%), 2013
Table 39: Global Pharmaceutical Manufacturers- Growth Projections in Developed Countries (%), 2013
Table 40: Global Pharmaceutical CROs and CMOs- Growth Projections in Developed Countries (%), 2013
Table 41: Global Pharmaceutical Industry Suppliers - Growth Projections in Developed Countries (%), 2013
Table 42: Global Pharmaceutical Industry - Increase in Growth Projections of Developed Countries by Turnover (%), 2013
Table 43: Global Pharmaceutical Industry - Leading Business Concerns (%), 2010-2013
Table 44: Global Pharmaceutical Industry - Leading Business Concerns by Company Type (%), 2013
Table 45: Global Pharmaceutical Industry - Leading Business Concerns by Region (%), 2013-2014
Table 46: Global Pharmaceutical Industry - Securing Buyer Business: Buyer vs. Supplier Responses (%), 2013
Table 47: Actions to Secure Buyer Business, Global Pharmaceutical Industry Buyer Responses (%), 2013
Table 48: Global Pharmaceutical Industry - Securing Buyer Business by Turnover (%), 2013
Table 49: Securing Buyer Business in the Global Pharmaceutical Industry - by Purchasing Decision Authority (%), 2013
Table 50: Annual Procurement Budgets of Global Pharmaceutical Industry Manufacturers in US$ (%), 2010-2013
Table 51: Global Pharmaceutical Industry Buyers - Increase in Revenue Growth vs. Procurement Budget (%), 2013
Table 52: Global Pharmaceutical Industry Buyers - Annual Procurement Budgets in US$ by Buyer Type (%), 2013
Table 53: Global Pharmaceutical Industry Buyers - Annual Procurement Budgets in US$ by Region(%), 2013
Table 54: Global Pharmaceutical Industry Buyers - Annual Procurement Budgets in US$ by Turnover (%), 2013
Table 55: Global Pharmaceutical Industry - Annual Procurement Budgets in US$ by Senior Level Respondents (%), 2013
Table 56: Change in Procurement Expenditure - Global Pharmaceutical Industry Buyers (%), 2010-2013
Table 57: Global Pharmaceutical Industry - Change in Procurement Expenditure by Buyer Type (%), 2013
Table 58: Global Pharmaceutical Industry - Change in Procurement Expenditure by Region (%), 2013
Table 59: Global Pharmaceutical Industry - Change in Procurement Expenditure by Turnover (%), 2013
Table 60: Global Pharmaceutical Industry - Change in Procurement Expenditure vs. Revenue Growth (%), 2013
Table 61: Global Pharmaceutical Industry - Change in Procurement Expenditure vs. Cost Containment (%), 2013
Table 62: Future Change in Expenditure by Product and Service Category, Pharmaceutical Industry Manufacturers (%), 2013
Table 63: Future Change in Expenditure by Product and Service Category, CROs and CMOs (%), 2013
Table 64: Increase in Expenditure by Product and Service Category - Buyers by Region , 2013
Table 65: Global Pharmaceutical Industry - Variations in Regional Supplier Prices (%), 2013
Table 66: Global Pharmaceutical Industry - Variations in Regional Supplier Prices by Company Type (%), 2013
Table 67: Global Pharmaceutical Industry - Variations in Regional Supplier Prices by Region (%), 2013
Table 68: Global Pharmaceutical Industry - Variations in Regional Supplier Prices by Turnover (%), 2013
Table 69: Critical Success Factors for Supplier Selection - Global Pharmaceutical Industry Buyers, 2013
Table 70: E-Procurement - Level of Implementation in the Global Pharmaceutical Industry (%), 2013
Table 71: E-Procurement in the Global Pharmaceutical Industry: by Buyer Type(%), 2013
Table 72: E-Procurement in the Global Pharmaceutical Industry by Region (%), 2013
Table 73: E-Procurement in the Global Pharmaceutical Industry by Turnover (%), 2013
Table 74: Survey Results - Closed Questions

List of Figures

Figure 1: Revenue Growth Optimism in the Global Pharmaceutical Industry (%), 2010-2013
Figure 2: Revenue Growth Optimism in the Global Pharmaceutical Industry by Company Type (%), 2010-2013
Figure 3: Revenue Growth Optimism in the Global Pharmaceutical Industry by Region (%), 2013
Figure 4: Revenue Growth Optimism in the Global Pharmaceutical Industry by Turnover (%), 2013
Figure 5: Revenue Growth Optimism by Senior Level Respondents - Global Pharmaceutical Industry (%), 2013
Figure 6: Key Expected Changes in Business Structure by Buyers - Global Pharmaceutical Industry (%), 2013
Figure 7: Key Expected Changes in Business Structure by Suppliers - Global Pharmaceutical Industry (%), 2013
Figure 8: Key Expected Changes in Business Structure by Region - Global Pharmaceutical Industry (%), 2013
Figure 9: Change in Leading Company Strategies by Buyers - Global Pharmaceutical Industry (%), 2013
Figure 10: Change in Leading Company Strategies by Suppliers - Global Pharmaceutical Industry (%), 2013
Figure 11: Change in Leading Company Strategies by Region - Global Pharmaceutical Industry (%), 2013
Figure 12: Change in Leading Company Strategies by Turnover - Global Pharmaceutical Industry (%), 2013
Figure 13: MandA Activity Projections - Global Pharmaceutical Industry (%), 2013
Figure 14: MandA Activity Projections - Global Pharmaceutical Manufacturers' Industry (%), 2010-2013
Figure 15: MandA Activity Projections - Global CROs and CMOs (%), 2010-2013
Figure 16: MandA Activity Projections - Global Pharmaceutical Industry Suppliers (%), 2010-2013
Figure 17: Global Pharmaceutical Industry MandA Activity Projections by Region (%), 2013
Figure 18: Global Pharmaceutical Industry MandA Activity Projections by Turnover (%), 2013
Figure 19: Global Pharmaceutical Industry MandA Activity Projections by Purchasing Decision Authority (%), 2013
Figure 20: Global Pharmaceutical Industry - Expand Abroad Vs MandA Activity Projections (%), 2013
Figure 21: Change in Capital Expenditure by Global Pharmaceutical Industry Manufacturers(%), 2013
Figure 22: Change in Capital Expenditure by Global CROs and CMOs (%), 2013
Figure 23: Change in Capital Expenditure by Pharmaceutical Industry Suppliers (%), 2013
Figure 24: Global Pharmaceutical Industry - Increase in Capital Expenditure by Turnover (%), 2013
Figure 25: Global Pharmaceutical Industry Manufacturers - Planned Change in Staff Recruitment (%), 2013
Figure 26: Global Pharmaceutical Industry Suppliers - Planned Change in Staff Recruitment Activity (%), 2013
Figure 27: Global Pharmaceutical Industry - Planned Change in Staff Recruitment Activity by Region (%), 2013
Figure 28: Global Pharmaceutical Industry - Planned Change in Staff Recruitment Activity by Turnover (%), 2013
Figure 29: Global Pharmaceutical Industry: Top Ten Growth Regions (%), 2013
Figure 30: Global Pharmaceutical Industry: Top Five Emerging Markets, 2013
Figure 31: Global Pharmaceutical Industry Manufacturers - Demand in Emerging Markets (%), 2013
Figure 32: Global Pharmaceutical Industry CROs and CMOs - Demand in Emerging Markets (%), 2013
Figure 33: Global Pharmaceutical Industry Suppliers - Demand in Emerging Markets (%), 2013
Figure 34: Global Pharmaceutical Industry - Demand in Emerging Markets by Region (%), 2013
Figure 35: Global Pharmaceutical Industry - Demand in Emerging Markets by Turnover (%), 2013
Figure 36: Global Pharmaceutical Industry - Top Five Developed Regions by Growth (%), 2013
Figure 37: Global Pharmaceutical Manufacturers- Growth Projections in Developed Countries (%), 2013
Figure 38: Global Pharmaceutical CROs and CMOs- Growth Projections in Developed Countries (%), 2013
Figure 39: Global Pharmaceutical Industry Suppliers - Growth Projections in Developed Countries (%), 2013
Figure 40: Global Pharmaceutical Industry - Increase in Growth Projections of Developed Countries by Region (%), 2013
Figure 41: Global Pharmaceutical Industry - Top Five Leading Business Concerns, 2013
Figure 42: Global Pharmaceutical Industry - Leading Business Concerns (%), 2013
Figure 43: Global Pharmaceutical Industry - Leading Business Concerns by Company Type (%), 2013
Figure 44: Global Pharmaceutical Industry - Leading Business Concerns by Turnover (%), 2013-2014
Figure 45: Global Pharmaceutical Industry - Securing Buyer Business: Buyer vs. Supplier Responses (%), 2013
Figure 46: Actions to Secure Buyer Business, Global Pharmaceutical Industry Buyer Responses (%), 2013
Figure 47: Global Pharmaceutical Industry - Securing Buyer Business by Region (%), 2013
Figure 48: Annual Procurement Budgets of Global Pharmaceutical Industry Manufacturers in US$ (%), 2010-2013
Figure 49: Global Pharmaceutical Industry Buyers - Annual Procurement Budgets in US$ by Buyer Type (%), 2013
Figure 50: Global Pharmaceutical Industry Buyers - Annual Procurement Budgets in US$ by Turnover (%), 2013
Figure 51: Global Pharmaceutical Industry - Annual Procurement Budgets in US$ by Senior Level Respondents (%), 2013
Figure 52: Change in Procurement Expenditure - Global Pharmaceutical Industry Buyers (%), 2010-2013
Figure 53: Global Pharmaceutical Industry - Change in Procurement Expenditure by Buyer Type (%), 2013
Figure 54: Global Pharmaceutical Industry - Change in Procurement Expenditure by Region (%), 2013
Figure 55: Global Pharmaceutical Industry - Change in Procurement Expenditure by Turnover (%), 2013
Figure 56: Future Change in Expenditure by Product and Service Category, Buyers , 2013
Figure 57: Future Change in Expenditure by Product and Service Category, Pharmaceutical Industry Manufacturers (%), 2013
Figure 58: Future Change in Expenditure by Product and Service Category, CROs and CMOs (%), 2013
Figure 59: Increase in Expenditure by Product and Service Category - Buyers by Turnover (%), 2013
Figure 60: Global Pharmaceutical Industry - Variations in Regional Supplier Prices (%), 2013
Figure 61: Global Pharmaceutical Industry - Variations in Regional Supplier Prices by Company Type (%), 2013
Figure 62: Global Pharmaceutical Industry - Variations in Regional Supplier Prices by Region (%), 2013
Figure 63: Critical Success Factors for Supplier Selection - Global Pharmaceutical Industry Buyers, 2013
Figure 64: E-Procurement - Level of Implementation in the Global Pharmaceutical Industry (%), 2013
Figure 65: E-Procurement in the Global Pharmaceutical Industry: by Buyer Type(%), 2013
Figure 66: E-Procurement in the Global Pharmaceutical Industry by Region (%), 2013
Figure 67: E-Procurement in the Global Pharmaceutical Industry: by Turnover (%), 2013

Companies Mentioned

Eli Lilly , Avid Radiopharmaceuticals , Roche , Johnson and Johnson , Mozambica , Mozambican Medicines Company , Mylan Pharmaceuticals Private Limited , AstraZeneca , MedImmune , WuXi AppTec , Pfizer , Bristol-Myers , Sanofi , Astellas Pharma , Sanwa Kagaku Kenkyusho , STS Health , Avita Medical , Guppy Plastics , Mylan Laboratories , TiGenix , DiaMedica , Suzhou Pharma , Arrowhead Research , Shire , biOasis Technologies , UCB , Immunovative Therapies , Lonza , UBICHEM Group , UBICHEM Pharma , BASF , Equateq , SAFC , Sigma-Aldrich , Semantelli , Novartis , UMN Pharma , Catalent Pharma Solutions , Sihuan Pharmaceutical Holdings , Dendreon Corporation , DBV Technologies , GENEWIZ , Bayer HealthCare Pharmaceuticals , Vitapath , Nextrials , LGC , Quotient Bioresearch , Bio-Rad Laboratories , AbD Serotec , MorphoSys AG , NextWave Pharmaceuticals , OPKO Health , DiscoveRx , BioSeek , Poxel , Nuron Biotech , Takeda, Takeda America Holdings, LigoCyte Pharmaceuticals, Block Engineering, Lexmark International, Acuo Technologies, Zhejiang Hisun Pharmaceuticals, Abbot, Essex Woodlands, Novavax, CPL Biologicals, Dr. Reddy's Laboratories, Debiopharm Group, Omkar Speciality Chemicals, Thermo Fisher Scientific, Bosch Packaging Technology, Amgen, TG Therapeutics, Ildong Pharmaceutical, Teva Pharmaceutical Industries, Handok Pharmaceuticals, GE Healthcare Life Sciences, GE Healthcare, Kiadis Pharma, Aptuit, Aegerion Pharmaceuticals, Novasep, ATS Labs, Galapagos and Cangenix

To order this report:
Pharmaceutical Industry:
Global Pharmaceutical Survey 2013-2014 - Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smart...
Complete Internet of Things (IoT) embedded device security is not just about the device but involves the entire product’s identity, data and control integrity, and services traversing the cloud. A device can no longer be looked at as an island; it is a part of a system. In fact, given the cross-domain interactions enabled by IoT it could be a part of many systems. Also, depending on where the device is deployed, for example, in the office building versus a factory floor or oil field, security ha...
An IoT product’s log files speak volumes about what’s happening with your products in the field, pinpointing current and potential issues, and enabling you to predict failures and save millions of dollars in inventory. But until recently, no one knew how to listen. In his session at @ThingsExpo, Dan Gettens, Chief Research Officer at OnProcess, discussed recent research by Massachusetts Institute of Technology and OnProcess Technology, where MIT created a new, breakthrough analytics model for s...
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
SYS-CON Events has announced today that Roger Strukhoff has been named conference chair of Cloud Expo and @ThingsExpo 2017 New York. The 20th Cloud Expo and 7th @ThingsExpo will take place on June 6-8, 2017, at the Javits Center in New York City, NY. "The Internet of Things brings trillions of dollars of opportunity to developers and enterprise IT, no matter how you measure it," stated Roger Strukhoff. "More importantly, it leverages the power of devices and the Internet to enable us all to im...
"We are the public cloud providers. We are currently providing 50% of the resources they need for doing e-commerce business in China and we are hosting about 60% of mobile gaming in China," explained Yi Zheng, CPO and VP of Engineering at CDS Global Cloud, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"We are a custom software development, engineering firm. We specialize in cloud applications from helping customers that have on-premise applications migrating to the cloud, to helping customers design brand new apps in the cloud. And we specialize in mobile apps," explained Peter Di Stefano, Vice President of Marketing at Impiger Technologies, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busin...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at 20th Cloud Expo, Ed Featherston, director/senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...
What happens when the different parts of a vehicle become smarter than the vehicle itself? As we move toward the era of smart everything, hundreds of entities in a vehicle that communicate with each other, the vehicle and external systems create a need for identity orchestration so that all entities work as a conglomerate. Much like an orchestra without a conductor, without the ability to secure, control, and connect the link between a vehicle’s head unit, devices, and systems and to manage the ...
Financial Technology has become a topic of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 20th Cloud Expo at the Javits Center in New York, June 6-8, 2017, will find fresh new content in a new track called FinTech.
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform and how we integrate our thinking to solve complicated problems. In his session at 19th Cloud Expo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and sh...
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of Soli...